FDA approves AbbVie's Juvmo, first D1/D5 dopamine agonist for Parkinson's disease

The FDA has approved AbbVie's Juvmo (tavapadon), the first once-daily oral D1/D5 selective dopamine agonist for adults with Parkinson's disease. Acquired through AbbVie's $8.7 billion takeover of Cerevel Therapeutics, Juvmo offers a novel mechanism that reduces motor symptoms with fewer side effects than traditional D2/D3-targeting therapies. Backed by strong Phase 3 TEMPO trial data, Juvmo will launch in the U.S. in October 2026, priced at $58,800 annually, targeting a $5 billion market.

Approval and launch timeline

• ▪The FDA approved AbbVie's Juvmo (tavapadon) as an oral, once-daily tablet for adults with Parkinson's disease on September 25, 2026.
• ▪AbbVie plans to make Juvmo commercially available to patients in the United States in October 2026.

Mechanism of action

• ▪Juvmo is the first and only approved dopamine agonist for Parkinson's disease that selectively targets D1 and D5 dopamine receptors.
• ▪By targeting D1/D5 receptors, Juvmo offers an alternative to existing dopamine agonists that primarily target D2/D3 receptors, reducing side effects like fatigue and impulse control behaviors.

Clinical trial results

• ▪In the TEMPO-1 clinical trial, early Parkinson's disease patients taking 5 mg and 15 mg of tavapadon saw significant combined MDS-UPDRS parts II and III score improvements of 9.7 and 10.2 points, respectively, at week 26.
• ▪After 85 weeks on tavapadon in clinical trials, 93% of participants did not increase their oral levodopa dose, and 94% of early Parkinson's patients did not start oral levodopa.
• ▪In the TEMPO-3 clinical trial, patients taking tavapadon as an adjunct to levodopa experienced a significant increase of 1.7 hours in daily 'on' time without troublesome dyskinesia at week 26.

Pricing and market potential

• ▪AbbVie will list Juvmo at a wholesale price of $4,900 per 30-day supply, which equates to $58,800 per year.
• ▪AbbVie Chief Commercial Officer Jeffrey Stewart stated that Juvmo could allow AbbVie to access a $5 billion market opportunity.

Cerevel Therapeutics acquisition context

• ▪The approval of Juvmo follows the November 2024 Phase II clinical trial failure of emraclidine, a schizophrenia drug that was the central asset of AbbVie's Cerevel acquisition.
• ▪AbbVie acquired tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics, which was announced in December 2023 and closed in August 2024.

Debatable claims

• ▪Juvmo's risk of serious side effects outweighs its clinical benefits for advanced Parkinson's patients
• ▪Juvmo's reduction in side effects makes it a superior alternative to traditional D2/D3 dopamine agonists
• ▪Juvmo's ability to delay levodopa escalation justifies its use as a first-line Parkinson's treatment
• ▪Juvmo's $58,800 annual price is justified by its clinical benefits over existing Parkinson's therapies